Completed PHASE3 INTERVENTIONAL 2-arm NCT00689611

Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial (ZESCA)

Sponsor: Canadian Institutes of Health Research (CIHR)

Conditions Acute Coronary Syndrome Myocardial Infarction Smoking

Updated 7 times since 2017 Last updated: Apr 10, 2015 Started: Dec 31, 2005 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute Coronary Syndrome and Myocardial Infarction, this trial is completed. The trial is conducted by Canadian Institutes of Health Research (CIHR) and has accumulated 7 data snapshots since 2005. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Canadian Institutes of Health Research (CIHR)
Heart and Stroke Foundation of Canada
Mark Eisenberg

Data source: McGill University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bay City, United States , Calgary, Canada , Charleston, United States , Cooperstown, United States , Dhaka, Bangladesh , Edmonton, Canada , Isfahan, Iran , Johnson City, United States , Karachi, Pakistan , Kentville, Canada and 23 more locations